Novartis A.G. v. YY

In the high-stakes world of pharmaceutical patents, time is not just money—it is market share, patient trust, and competitive advantage. When a multinational innovator like Novartis A.G. discovers its patented technology is being allegedly infringed upon, every day spent in procedural delays can mean irreparable commercial damage. This case raises a critical question for founders and IP professionals: when the law demands mediation before litigation, what happens when waiting simply isn't an option?

Novartis A.G., one of the world's leading pharmaceutical companies, along with its affiliate, found themselves in a position no innovator wants to be in—allegations that their patented innovation, protected under Indian Patent No. 419280, was being infringed upon by another party. Rather than waiting on the sidelines, Novartis took decisive legal action by filing a suit seeking a permanent injunction to stop the alleged infringement. The dispute set the stage for a confrontation not just over the patent itself, but over the procedural pathway to enforcing it.

At the heart of this legal confrontation was a procedural tug-of-war. On one side stood Novartis and its affiliate, arguing that the alleged infringement demanded urgent judicial intervention. Their position was clear: any delay in restraining the alleged infringer could result in continued unauthorized use of their patented technology, causing harm that could not be undone through monetary compensation alone. On the other side loomed the procedural framework itself—the mandatory requirement of pre-institution mediation, a step designed to encourage settlement before parties escalate to formal litigation. The central friction was this: should a plaintiff seeking urgent interim relief be forced to first complete mediation, or could the court carve out an exception when time-sensitive protection is at stake?

The court sided with urgency over procedural formality. Recognizing the nature of the relief sought—a permanent injunction in a patent infringement matter—the court granted several interlocutory orders in favor of Novartis and its affiliate. Most significantly, the court granted an interim injunction, providing immediate protection to the patentee's rights pending the outcome of the full case. Equally important, the court granted an exemption from the mandatory pre-litigation mediation requirement. Drawing on Supreme Court judgments, the court reasoned that when a suit contemplates urgent interim relief, forcing parties through mediation first would defeat the very purpose of seeking timely judicial protection. The outcome was an interim order, signaling that the battle is far from over, but Novartis secured the immediate shield it needed.

For founders, startup leaders, and IP professionals, this case delivers a clear and actionable lesson: when pursuing IP infringement claims, urgency matters—and courts recognize it. If your business faces alleged infringement of a patent, trademark, or other intellectual property right, do not assume that mandatory pre-litigation mediation will be your only path. Build a compelling case demonstrating why immediate judicial intervention is necessary, and reference established precedents that support exemptions when urgent interim relief is contemplated. The lesson is simple but powerful: in IP disputes, the strongest legal strategies are those that frame delay not as patience, but as potential irreparable harm.